The clinical pharmacologist in drug regulation: The US perspective

British Journal of Clinical Pharmacology

Volumn 42, Issue 1, 1996, Pages 73-79

  Temple, R J ^a  

^a Center for Drug Evaluation and Research   (United States)

Author keywords

Clinical pharmacologist; Pharmacodynamics

Indexed keywords

ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BISOPROLOL; CAPTOPRIL; CARDIOVASCULAR AGENT; CHLORTALIDONE; DIURETIC AGENT; ERYTHROMYCIN; GUANFACINE; KETOCONAZOLE; THALIDOMIDE;

AGE; CLINICAL PHARMACOLOGY; CONFERENCE PAPER; DOSE RESPONSE; DRUG CONTROL; DRUG DEVELOPMENT; DRUG REGULATION; DRUG RESPONSE; DRUG SAFETY; HUMAN; INDIVIDUALIZATION; PHARMACIST; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; UNITED STATES;

EID: 0029683030     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis: report of an outbreak. Am Rev Resp Dis 1972; 106:357-365.
2. Materson BJ, Oster JR, Michael UF, et al. Dose-response to chlorthalidone in patients with mild hypertension. Clin Pharmacol Ther 1978; 24:192-198.
3. Tweeddale MG, Ogilvie RI, Rudey J. Antihypertensive and biochemical effects of chlorthalidone. Clin Pharmacol Ther 1977; 22:519-527.
4. Temple R. Food and Drug Administration's Guidelines for Clinical Testing of Drugs in the Elderly. Drug Information 1985; 19:483-486.
5. Honig PK, Wortham DC, Zamani K, Connor DP, Mullin JC, Cantilena LR. Terfenidine-ketoconazole interaction; pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269:1513-1518.
6. Honig PK, Woosley RL, Zamanik, Conner DR, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenidine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52:231-238.
7. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992; 51:239-248.
8. Wu CY, Benet LL, Hebert M, et al. Differentiation of absorption, and first-pass gut and hepatic metabolism in humans studies with cyclosporin. Clin Pharmacol Ther 1995; 58:492-497.
9. Oates NS, Shah RR, Idle JR, Smith RL. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin Pharmacol Ther 1983; 34:827-834.
10. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JDF. Impaired oxidation of debrisoquine in patients with perhexilene neuropathy. Br Med J 1982; 284:295-299.
11. Idle JR, Smith RL. Pharmacogenetics in the new patterns of healthcare delivery. Pharmacogenetics 1995; 5:347-350.
12. Jaehde V, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther 1995; 58:532-541.
13. Sheiner LB, Beal SB, Sambol NC. Study designs for dose-ranging. Clin Pharmacol Ther 1989; 46:63-77.